Literature DB >> 12851665

The BC Community Pharmacy Asthma Study: A study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia.

William McLean1, Jane Gillis, Ron Waller.   

Abstract

OBJECTIVES: Despite advances in recent years, asthma morbidity and mortality have been noted to be on the increase in the past decade. The present study examined the failures and recommendations of past studies and introduced a new milieu for asthma care--the community pharmacy. The study incorporated a care protocol with the important ingredients of asthma education on medications, triggers, self-monitoring and an asthma plan, with pharmacists taking responsibility for outcomes, assessment of a patient's readiness to change and tailoring education to that readiness, compliance monitoring and physician consultation to achieve asthma prescribing guidelines.
METHODS: Thirty-three pharmacists in British Columbia, specially trained and certified in asthma care, agreed to participate in a study in which experienced pharmacists would have asthma patients allocated to enhanced (pharmaceutical) care (EC) or usual care (UC). Pharmacists less experienced were clustered by geography and had their pharmacies randomized to two levels of care; each pharmacy then had patients randomized to EC versus control, UC versus control or EC versus UC depending on their pharmacy randomization. Six hundred thirty-one patients provided consent, of which 225 in EC or UC were analyzed for all outcomes. Patients were followed for one year.
RESULTS: Compared with patients in the UC group, the results of those in the EC group were as follows: symptom scores decreased by 50%; peak flow readings increased by 11%; days off work or school were reduced by approximately 0.6 days/month; use of inhaled beta-agonists was reduced by 50%; overall quality of life improved by 19%, and the specific domains of activity limitations, symptoms and emotional function also improved; initial knowledge scores doubled; emergency room visits decreased by 75%; and medical visits decreased by 75%. A patient satisfaction survey revealed that the population was extremely pleased with their pharmacy services. Cost analysis reinforces the EC model, which is more cost effective than UC in terms of most direct and indirect costs in asthma patients.
CONCLUSION: Specially trained community pharmacists in Canada, using a pharmaceutical care-based protocol, can produce impressive improvements in clinical, economic and humanistic outcome measures in asthma patients. The health care system needs to produce incentives for such care.

Entities:  

Mesh:

Year:  2003        PMID: 12851665     DOI: 10.1155/2003/736042

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  35 in total

1.  Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community.

Authors:  Carol Armour; Sinthia Bosnic-Anticevich; Martha Brillant; Debbie Burton; Lynne Emmerton; Ines Krass; Bandana Saini; Lorraine Smith; Kay Stewart
Journal:  Thorax       Date:  2007-01-24       Impact factor: 9.139

2.  Complex pharmaceutical care intervention in pulmonary care: part A. The process and pharmacists' professional satisfaction.

Authors:  Ada G G Stuurman-Bieze; Willem O de Boer; Mirjam E A P Kokenberg; Jacqueline G Hugtenburg; Lolkje T W de Jong-van den Berg; Th F J Tromp
Journal:  Pharm World Sci       Date:  2005-10

3.  Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review.

Authors:  Dalia M Dawoud; Alexander Haines; David Wonderling; Joanna Ashe; Jennifer Hill; Mihir Varia; Philip Dyer; Julian Bion
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

4.  Designing a novel continuing education program for pharmacists: Lessons learned.

Authors:  Barbara Farrell; Lisa Dolovich; Phil Emberley; Marie-Anik Gagné; Brad Jennings; Derek Jorgenson; Natalie Kennie; Pia Zeni Marks; Christine Papoushek; Nancy Waite; Donna M M Woloschuk
Journal:  Can Pharm J (Ott)       Date:  2012-07

5.  A role for pharmacists in respiratory education.

Authors:  Kristine L Petrasko
Journal:  Can Pharm J (Ott)       Date:  2012-03

6.  Investigation on barriers to pharmaceutical care in community pharmacies: a structural equation model.

Authors:  Gholamhossein Mehralian; Maryam Rangchian; Athar Javadi; Farzad Peiravian
Journal:  Int J Clin Pharm       Date:  2014-08-29

Review 7.  A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions.

Authors:  Rachel A Elliott; Koen Putman; James Davies; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

8.  Pharmacist-led intervention study to improve drug therapy in asthma and COPD patients.

Authors:  Stefan Ottenbros; Martina Teichert; Romy de Groot; Fabienne Griens; Fong Sodihardjo; Michel Wensing; J J de Gier
Journal:  Int J Clin Pharm       Date:  2013-12-01

9.  Improving Drug Benefits for Children with Asthma: Results of a Multi-stakeholder Workshop to Build a Research Agenda.

Authors:  Wendy J Ungar; Michael Paterson; Shannon Cope; Anita Kozyrskyj
Journal:  Healthc Policy       Date:  2008-05

10.  Implementing practice guidelines: a workshop on guidelines dissemination and implementation with a focus on asthma and COPD.

Authors:  Louis-Philippe Boulet; Allan Becker; Dennis Bowie; Paul Hernandez; Andrew McIvor; Michel Rouleau; Jean Bourbeau; Ian D Graham; Jo Logan; France Légaré; Thomas F Ward; Robert L Cowie; Denis Drouin; Stewart B Harris; Robyn Tamblyn; Pierre Ernst; Wan C Tan; Martyn R Partridge; Philippe Godard; Carla T Herrerias; John W Wilson; Liz Stirling; Emily-Brynn Rozitis; Nancy Garvey; Diane Lougheed; Manon Labrecque; Renata Rea; Martin C Holroyde; Danielle Fagnan; Eileen Dorval; Lisa Pogany; Alan Kaplan; Lisa Cicutto; Mary L Allen; Serge Moraca; J Mark FitzGerald; Francine Borduas
Journal:  Can Respir J       Date:  2006-03       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.